Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
ClearNote Health
Summary
ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors.
Description
Epigenomic changes in cancer cells can provide a rich source of biomarker signals for the detection of disease. As cancer cells manifest their epigenomic changes in blood due to cell death, DNA and protein molecules can be probed using specific molecular analytic approaches. ClearNote Health employs epigenomic technologies to measure dynamic changes in DNA demethylation events via direct measurement of 5-hydroxymethyl-cytosine residues in cfDNA. Companion assays are also run to provide information on cfDNA digestion patterns and protein-based changes in plasma. This information, combined in a…
Eligibility
- Age range
- 21–80 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria 1. Subjects must be between 21-80 years of age at the time of enrollment 2. Patient fully consented 3. Cancer diagnosis OR high clinical suspicion for cancer, based on the participating site's and practitioner's standards of care (SOC) 4. No previous history of cancer and treatment naïve at time of enrollment Exclusion Criteria 1. Age \< 21 OR \> 80 years of age 2. Any prior cancer diagnosis with or without treatment (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment) 3. Receipt of any cancer therapy including chemotherapy, rad…
Interventions
- OtherBlood Draw
Blood Draw
Location
- ClearNote Health, Inc.San Diego, California